In the ChAd/ChAd-primed participants, the median age was 53 years (IQR 44–61) in the younger group and 76 years (73–78) in the older group. The coprimary outcomes were safety and immunogenicity of anti-spike IgG measured by ELISA at day 28.
FOCUS BOOSTER UK TRIAL
This multicentre UK trial recruited 2878 healthy participants older than 30 years across 18 sites who had received either two doses of BNT162b2 or ChAdOx1 nCov-19, with no history of previous SARS-CoV-2 infection, and randomly assigned them to receive one of seven COVID-19 vaccines namely, NVX-CoV2373 (Novavax, NVX), ChAdOx1 nCov-19 (Oxford–AstraZeneca, ChAd), BNT162b2 (Pfizer–BioNtech, BNT), VLA2001 (Valneva, VLA), (Janssen), mRNA1273 (Moderna, m1273), CVnCov (CureVac), three of which were also used as half doses (BNT, VLA, and NVX) or a quadrivalent meningococcal conjugate vaccine (MenACWY) as a control. In The Lancet, Alasdair Munro and colleagues 10 report the outcomes of the COV-BOOST trial, which is timely and provides valuable evidence on the immunogenicity and safety of seven COVID-19 vaccines administered as boosters.
7 Additionally, with concerns around the mutational profile of omicron, with WHO designating it a variant of concern on Nov 26, 2021, 5 acceleration of a third dose in the UK was proposed as a key response strategy for COVID-19, resulting in widening eligibility to all people aged 18 years and older and reducing the minimum time interval between doses two and three. With emerging evidence from Israel and the UK of vaccine waning, the Joint Committee on Vaccination and Immunisation (JCVI) in September, 2021, recommended boosting individuals in a phased way 6 months after completion of their primary course of COVID-19 immunisation. 6 In the UK, the COVID-19 vaccination campaign launched in December, 2020, and began with prioritised population groups, including people most likely to be at higher risk for severe outcomes or those providing health services or care for these individuals. With accruing evidence that the effectiveness of COVID-19 vaccines wanes over time, 1, 2, 3, 4 and the recent emergence of the omicron (B.1.1.529) variant, 5 some countries are rapidly deploying vaccine boosters.
0 kommentar(er)
